GMP manufacturing & GLP diagnostic: Towards a personalised phage therapy against antimicrobial resistance

Fact Sheet

Project Information

PhagoPROD

Grant agreement ID: 811749

Project website

DOI
10.3030/811749

Project closed

EC signature date
25 July 2018

Start date
1 November 2018

End date
31 December 2021

Funded under
INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost
€ 3 929 376,00

EU contribution
€ 2 446 712,00

Coordinated by
PHERECYDES PHARMA SA
France

Objective

Phage therapy, that is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections, is a highly promising answer to the antibiotic resistant plague (500 000 deaths a year attributable to multi-drug resistant bacteria today, 10 million forecast by 2050). In this hopeful field, Pherecydes Pharma, a French SME created in 2006, is currently the world leader of phage therapy, with a a unique

selling point and value proposal: (1) Patented technology; (2) Curent product portfolio covering over 50% of human infections and almost 90% of multi-drug resistant ones; (3) Ability to manufacture phages in GMP conditions; (4) 1st company to launch a transnational, well-designed, well-controlled, multicentric clinical study; (5) French authorisation (ANSM) in 2017 to administrate Pherecydes Pharma bacteriophages under a compassionate use status. Building on these successes, the PhagoPROD project aims at setting-up, optimising and scaling-up the GMP manufacturing and GLP diagnostics processes currently validated and demonstrated at laboratory scale. In that so, the ultimate objective is to achieve large-scale commercial exploitation of Pherecydes Pharma products first at the EU then at the USA levels (world reaching is planned in the long term). In the frame of this future commercial exploitation, targeted final users will be patients suffering from bacterial infections, notably antibiotic-resistant ones. Customers (i.e. buyers of Pherecydes Pharma products) will be clinical prescribers and hospital pharmacists. In this regard, Pherecydes already benefits from strong and long-lasting relationships with many hospitals and clinical centres in France and in Europe, as well as with several patients' associations (e.g. Le Lien or Phagespoirs).

Fields of science (EuroSciVoc)

natural sciences > biological sciences > microbiology > **bacteriology**

medical and health sciences > basic medicine > pharmacology and pharmacy > **pharmaceutical drugs**

natural sciences > biological sciences > microbiology > **virology**

medical and health sciences > basic medicine > pharmacology and pharmacy > drug resistance > **multidrug resistance**

medical and health sciences > basic medicine > pharmacology and pharmacy > drug resistance > **antibiotic resistance**

Programme(s)

H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs MAIN PROGRAMME

H2020-EU.3. - PRIORITY 'Societal challenges

H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

PHERECYDES PHARMA SA

Net EU contribution

€ 2 446 712,00

Total cost

€ 3 929 376,00

Address

NANTES BIOTECH 22 BOULEVARD BENONI GOULLIN
44200 NANTES
France

SME

Yes

Region

Pays de la Loire > Pays de la Loire > Loire-Atlantique

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Contact the organisation Website
Participation in EU R&I programmes
HORIZON collaboration network

Last update: 22 September 2022